ANRO — Alto Neuroscience, Inc.

Is ANRO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Alto Neuroscience, Inc. (ANRO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $24.80. The rating moved from Strong Oversold to Oversold on September 25, 2026.

See all oversold Healthcare stocks →

AI analysis

Alto Neuroscience, Inc. is an early-stage specialty biotech whose near-term trajectory depends on clinical readouts and ability to fund development. The company benefits from scientific differentiation in neuroscience/psychiatry but currently lacks commercial revenue, making valuation sensitive to trial outcomes and capital-market conditions. Absent clear upcoming catalysts or a secured extended runway, performance is likely to be driven by binary events and wider market risk sentiment.

Key factors

  • Early-stage clinical pipeline focused on neurological/psychiatric indications with potential for differentiated, precision approaches
  • Limited or no meaningful commercial revenue today — valuation and outlook driven primarily by clinical readouts and financing/cash runway
  • Macro risk-off environment and cooling IPO window reduce near-term capital access and investor appetite for pre-revenue biotechs
  • Sector tailwinds for conviction biotech investors in select late-stage names could support episodic interest if translational data are strong
  • Ongoing policy focus on drug pricing and Medicare negotiation increases pricing and access uncertainty for novel therapies
  • Low available social/research sentiment data increases short-term informational opacity and makes market moves catalyst-driven

Risks

  • Clinical trial failure or negative translational data that materially reduces probability of approval for lead programs
  • Financing and dilution risk if cash runway is limited and capital markets remain constrained
  • Heightened payer pressure, Medicare negotiation, and pricing scrutiny that could erode future revenue potential or access
  • Competition from larger biotech/pharma or alternative modality players with deeper commercial capabilities
  • Regulatory delay or additional data requirements that extend timelines and increase costs
  • Market volatility and sector rotation into defensive assets creating temporary liquidity/valuation pressure

See today's live rating, score and targets

Members see the live hourly rating for ANRO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.